Financhill is a comprehensive financial analysis platform that provides stock analysis, market data, investment tools, and educational resources to help investors make informed decisions.

How do I get started with Financhill?

You can start by creating a free account, exploring our stock analysis tools, setting up a watchlist, or trying our 7-day trial for full access to all premium features.

What features does Financhill offer?

Financhill offers stock analysis, technical charts, fundamental data, earnings information, dividend tracking, portfolio management, market screening tools, and educational resources.

What are 10K annual reports?

10K reports are comprehensive annual reports filed by public companies with the SEC, containing detailed financial statements, business operations, risk factors, and management discussion.

How often are annual reports updated?

Annual reports are typically filed once per year, usually within 60-90 days after the company's fiscal year end. We update our database as soon as new reports become available.

How do I analyze KROS stock?

Use our comprehensive analysis tools including technical charts, fundamental metrics, earnings data, and Stock Score to evaluate KROS investment potential.

What is KROS stock price today?

Get real-time KROS stock price, historical data, and price charts on Financhill. Track KROS performance with our advanced analysis tools.

Is KROS a good investment?

Evaluate KROS investment potential using our Stock Score, fundamental analysis, technical indicators, and earnings data. Consider your risk tolerance and investment goals.

How to buy KROS stock?

To buy KROS stock, open a brokerage account, research the company using our analysis tools, and place your order through your broker. Always do your own research before investing.

What is the market cap of KROS?

View detailed market capitalization data and company valuation metrics for KROS on our comprehensive analysis page.

What is the P/E ratio of KROS?

Use our fundamental analysis tools to view KROS P/E ratio and compare valuation metrics with industry peers.

What are KROS earnings?

View KROS earnings data, quarterly results, revenue growth, and profit margins on our comprehensive earnings analysis page. Track earnings trends and analyst estimates.

Back

Keros Therapeutics, Inc. 10K Form

Buy

KROS
Keros Therapeutics, Inc.

Last Price:

$21.28

Seasonality Move:

6.31%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive KROS News And Ratings

See the #1 stock for the next 7 days that we like better than KROS

KROS Financial Statistics

Sales & Book Value

Annual Sales:	$3.6M
Cash Flow:	$3.1M
Price / Cash Flow:	10.12
Annual Sales:	$17.32
Price / Book:	0.94

Profitability

EPS (TTM):	1.54290
Net Income (TTM):	$64.4M
Gross Margin:	$2.3M
Return on Equity:	9.94%
Return on Assets:	9.26%

Keros Therapeutics, Inc. Earnings Forecast

Key Keros Therapeutics, Inc. Financial Ratios

The Gross Profit Margin over the past 7 years for KROS is 65.38%.
The Selling, General & Administrative Expenses for KROS have been equal to 1,148.00% of Gross Profit Margin.
The Research & Development expenses have been 4,890.96% of Revenue.
The Net Earning history of KROS is -5,277.55% of Total Revenues.
Per Share Earnings over the last 7 years have been positive in 2 years.

Keros Therapeutics, Inc. Stock Price Chart

Industry, Sector and Symbol

Stock Exchange:	NASDAQ
Industry:	Biotechnology
Sector:	Health Care
Current Symbol:	KROS
CUSIP:	492327
Website:	kerostx.com

Debt

Debt-to-Equity Ratio:	0.02
Current Ratio:	29.86
Quick Ratio:	28.93

Price-to-Earnings

Trailing P/E Ratio:	0
Forward P/E Ratio:	0

KROS Technical Analysis vs Fundamental Analysis

Buy

Keros Therapeutics, Inc. (KROS) is a Buy

Is Keros Therapeutics, Inc. a Buy or a Sell?

Keros Therapeutics, Inc. stock is rated a Buy

The current Keros Therapeutics, Inc. [KROS] share price is $21.69. The Score for KROS is 60, which is 20% above its historic median score of 50, and infers lower risk than normal.